Method Development for Simultaneously Determining Indomethacin and Nicotinamide in New Combination in Oral Dosage Formulations and Co-Amorphous Systems Using Three UV Spectrophotometric Techniques
Table 7
Data of the comparison between the proposed methods and reference methods.
Sample number
Indomethacin in IR capsules1
Pure nicotinamide2
ZCD2
DWD1
SS
BP19 HPLC
ZCD2
DWD1
RS
BP19 UV
Recovery%
1
100.04
100.58
101.32
99.55
100.21
100.23
99.13
100.14
2
101.09
100.61
101.22
98.74
99.02
99.95
98.96
99.97
3
101.04
99.79
100.89
100.21
98.04
99.82
98.85
99.86
4
101.27
100.86
100.15
100.80
98.10
99.73
98.53
99.53
5
101.46
101.25
100.42
101.12
98.55
99.54
100.30
99.30
6
—
—
—
—
98.34
99.82
98.07
99.06
Mean recovery%
100.98
100.62
100.80
100.08
98.71
99.85
98.97
99.64
SD
0.5509
0.5350
0.5054
0.9609
0.8160
0.2309
0.7500
0.4166
Standard error
0.2464
0.2393
0.2260
0.4297
0.3332
0.0943
0.3062
0.1701
Variance
0.3034
0.2863
0.2554
0.9233
0.6659
0.0533
0.5625
0.1736
t-test with ref method
1.809
1.086
1.475
—
2.490
1.064
1.908
—
F-test with ref method
3.043
3.225
3.615
—
3.837
3.254
3.241
—
1The number of samples of immediate-release capsules was 5 (n = 5). 2The number of samples of pure nicotinamide was 6 (n = 6). The reference methods to be compared with. Critical values of the two-tailed test in 5% significance level are 2.776 for n = 5 and 2.571 for n = 6. Critical values of the F-test in 5% significance level are 6.39 for n = 5 and 5.05 for n = 6.
